Piet Wigerinck, PhD, is the former CSO of Galapagos. Under his leadership, Galapagos has developed a large pipeline of novel mechanism of action drugs for auto-immune diseases; Jyseleca was approved for rheumatoid arthritis in 2020 in the EU and Japan. He has supervised multiple successful proofs-of-concept patient studies, including filgotinib and ziritaxestat. Prior to his tenure at Galapagos, he was Vice President, Drug Discovery, Early Development and CM&C at Tibotec-Virco Comm. VA (a subsidiary of Johnson & Johnson). Under his leadership at Tibotec, Prezista™, Olysio™, and Rekambys™ were selected, moved forward into clinical trials and were later approved. Piet Wigerinck has over 30 years of R&D experience in the pharmaceutical industry and biotechnology. He is an independent board member of various Biotech and Pharma including the French pharma company Ipsen SA.